IP4 and INNPF Related Headlines
Go Back- Innocan Pharma Reports 2025 Financial Results, with Revenues at US $26.6M
- Innocan Pharma Announces LPT-CBD demonstrates Pain Relief over Placebo-Results from a randomized blinded clinical study in Dogs
- Innocan Pharma plans NYSE American listing around January 30
- Innocan Pharma Corporation Anticipates Listing on the NYSE American Stock Exchange with Concurrent Offering
- Innocan Pharma anticipates NYSE American listing around January 7
- Innocan Pharma Corporation Anticipates Listing on the NYSE American Stock Exchange with Concurrent Offering
IP4 and INNPF Related Press Releases
Go Back- Innocan Pharma Reports 2025 Financial Results, with Revenues at US $26.6M
- Innocan Pharma Announces LPT-CBD demonstrates Pain Relief over Placebo-Results from a randomized blinded clinical study in Dogs
- Innocan Pharma Corporation Anticipates Listing on the NYSE American Stock Exchange with Concurrent Offering
- Innocan Pharma Corporation Anticipates Listing on the NYSE American Stock Exchange with Concurrent Offering
